新型8-甲氧基喹诺酮类药物Bay 12-8039的体外活性
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.
作者信息
Fass R J
机构信息
Department of Internal Medicine, Ohio State University College of Medicine, Columbus 43210, USA.
出版信息
Antimicrob Agents Chemother. 1997 Aug;41(8):1818-24. doi: 10.1128/AAC.41.8.1818.
Abstract
MICs of Bay 12-8039 and comparative antimicrobials were determined for 820 recent clinical isolates. Ciprofloxacin was approximately 2-fold more active than Bay 12-8039 and ofloxacin against Enterobacteriaceae and approximately 8-fold more active against Pseudomonas aeruginosa. Bay 12-8039 was approximately 2- to 16-fold more active than ciproiloxacin and ofloxacin against nonfermenters (except P. aeruginosa), staphylococci, streptococci, enterococci, and anaerobes. As determined by regression analysis, there was a high degree of correlation among quinolone MICs.
摘要
对820株近期临床分离菌株测定了Bay 12-8039及对照抗菌药物的最低抑菌浓度（MIC）。环丙沙星对肠杆菌科细菌的活性比Bay 12-8039和氧氟沙星高约2倍，对铜绿假单胞菌的活性高约8倍。Bay 12-8039对非发酵菌（铜绿假单胞菌除外）、葡萄球菌、链球菌、肠球菌和厌氧菌的活性比环丙沙星和氧氟沙星高约2至16倍。通过回归分析确定，喹诺酮类药物的MIC之间存在高度相关性。
相似文献
1
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.新型8-甲氧基喹诺酮类药物Bay 12-8039的体外活性
Antimicrob Agents Chemother. 1997 Aug;41(8):1818-24. doi: 10.1128/AAC.41.8.1818.
2
Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.新型喹诺酮类药物Bay 12 - 8039与其他抗菌药物对临床重要厌氧菌的体外活性比较。
Antimicrob Agents Chemother. 1997 Mar;41(3):709-11. doi: 10.1128/AAC.41.3.709.
3
In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolates.新型喹诺酮类药物莫西沙星（拜耳12-8039）对革兰氏阳性耐药临床分离株的体外活性。
Diagn Microbiol Infect Dis. 1999 Jan;33(1):27-31. doi: 10.1016/s0732-8893(98)00129-1.
4
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.新型8-甲氧基喹诺酮BAY 12-8039对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1998 Apr;42(4):951-2. doi: 10.1128/AAC.42.4.951.
5
Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria.Bay 12 - 8039，一种新型8 - 甲氧基喹诺酮：与其他九种抗菌药物对厌氧菌的体外活性比较
J Antimicrob Chemother. 1997 Oct;40(4):503-9. doi: 10.1093/jac/40.4.503.
6
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.喹诺酮类药物Bay 12 - 8039、加替沙星（AM 1155）、曲伐沙星、克林沙星、左氧氟沙星和环丙沙星抗菌活性的比较。
J Antimicrob Chemother. 1997 Nov;40(5):639-51. doi: 10.1093/jac/40.5.639.
7
In vitro activity of BAY 12-8039, a new fluoroquinolone.新型氟喹诺酮类药物BAY 12 - 8039的体外活性
Antimicrob Agents Chemother. 1997 Jan;41(1):101-6. doi: 10.1128/AAC.41.1.101.
8
Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.环丙沙星与新型8-甲氧基喹诺酮类药物莫西沙星对耐甲氧西林金黄色葡萄球菌的细胞内活性
J Antimicrob Chemother. 1998 Jun;41(6):655-8. doi: 10.1093/jac/41.6.655.
9
Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.莫西沙星对环丙沙星敏感性降低的病原体的活性。
J Antimicrob Chemother. 1999 Nov;44(5):621-7. doi: 10.1093/jac/44.5.621.
10
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.新型8-甲氧基喹诺酮类药物Bay 12-8039与其他11种口服抗菌药物对从人类和动物咬伤伤口皮肤及软组织感染中分离出的390株需氧菌和厌氧菌的体外活性比较。
Antimicrob Agents Chemother. 1997 Jul;41(7):1552-7. doi: 10.1128/AAC.41.7.1552.
引用本文的文献
1
Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis.莫西沙星治疗 2338 例慢性支气管炎急性加重患者的疗效和耐受性。
Clin Drug Investig. 2003;23(1):1-10. doi: 10.2165/00044011-200323010-00001.
2
The new fluoroquinolones: A critical review.新型氟喹诺酮类药物：批判性综述。
Can J Infect Dis. 1999 May;10(3):207-38. doi: 10.1155/1999/378394.
3
Moxifloxacin in the treatment of skin and skin structure infections.莫西沙星治疗皮肤和皮肤结构感染。
Ther Clin Risk Manag. 2006 Dec;2(4):417-34. doi: 10.2147/tcrm.2006.2.4.417.
4
Efficacy and tolerability of moxifloxacin in patients with sinusitis treated in general practice : results of a post-marketing surveillance study.莫西沙星治疗普通科门诊鼻窦炎患者的疗效和耐受性：上市后监测研究结果。
Clin Drug Investig. 2004;24(8):431-9. doi: 10.2165/00044011-200424080-00001.
5
Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.莫西沙星联合哌拉西林-他唑巴坦或头孢吡肟对肺炎克雷伯菌、阴沟肠杆菌和鲍曼不动杆菌临床分离株的协同活性。
Antimicrob Agents Chemother. 2004 Mar;48(3):1055-7. doi: 10.1128/AAC.48.3.1055-1057.2004.
6
New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones with various substituents at position 1.1位带有不同取代基的氟喹诺酮类药物的结构与光毒性关系及光稳定性的新发现。
Antimicrob Agents Chemother. 2004 Mar;48(3):799-803. doi: 10.1128/AAC.48.3.799-803.2004.
7
Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.来自德国的空肠弯曲菌分离株对环丙沙星、莫西沙星、红霉素、克林霉素和四环素的敏感性。
Antimicrob Agents Chemother. 2003 Jul;47(7):2358-61. doi: 10.1128/AAC.47.7.2358-2361.2003.
8
A critical review of the fluoroquinolones: focus on respiratory infections.氟喹诺酮类药物的批判性综述：聚焦于呼吸道感染
Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002.
9
Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii.莫西沙星对贝氏柯克斯体的抑菌和杀菌活性。
Antimicrob Agents Chemother. 2001 Jan;45(1):301-2. doi: 10.1128/AAC.45.1.301-302.2001.
10
Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.莫西沙星单独及与乙胺丁醇、利福布汀和阿奇霉素联合在体外和体内对鸟分枝杆菌的活性。
Antimicrob Agents Chemother. 2001 Jan;45(1):217-22. doi: 10.1128/AAC.45.1.217-222.2001.
本文引用的文献
1
In vitro activity of BAY 12-8039, a new fluoroquinolone.新型氟喹诺酮类药物BAY 12 - 8039的体外活性
Antimicrob Agents Chemother. 1997 Jan;41(1):101-6. doi: 10.1128/AAC.41.1.101.
2
In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.喹诺酮类、β-内酰胺类、妥布霉素及甲氧苄啶-磺胺甲恶唑对非发酵革兰氏阴性杆菌的体外活性
Antimicrob Agents Chemother. 1996 Jun;40(6):1412-8. doi: 10.1128/AAC.40.6.1412.
3
In vitro activity of Bay y 3118, a new quinolone.新型喹诺酮类药物Bay y 3118的体外活性
Antimicrob Agents Chemother. 1993 Nov;37(11):2348-57. doi: 10.1128/AAC.37.11.2348.
4
Use of frequency distribution curves, scattergrams and regression analyses to compare in vitro activities and describe cross-susceptibility and cross-resistance among four quinolones.
J Chemother. 1994 Dec;6(6):368-76. doi: 10.1080/1120009x.1994.11736491.
5
In vitro activity of ciprofloxacin (Bay o 9867).环丙沙星（拜耳o 9867）的体外活性。
Antimicrob Agents Chemother. 1983 Oct;24(4):568-74. doi: 10.1128/AAC.24.4.568.
6
In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.对五种喹诺酮类药物的体外研究：随着喹诺酮类耐药性上升，相对效力变化的证据。
Antimicrob Agents Chemother. 1991 Nov;35(11):2329-34. doi: 10.1128/AAC.35.11.2329.
7
Cross-resistance and cross-susceptibility between fluoroquinolone agents.氟喹诺酮类药物之间的交叉耐药性和交叉敏感性。
Eur J Clin Microbiol Infect Dis. 1991 Dec;10(12):1013-8. doi: 10.1007/BF01984922.
8
The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.新型氟喹诺酮类药物托氟沙星与环丙沙星和替马沙星的体外活性比较。
J Antimicrob Chemother. 1991 Nov;28(5):719-25. doi: 10.1093/jac/28.5.719.
Zotero 插件